# A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

> **NCT06820749** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 309 (estimated)

## Conditions studied

- Asthma Bronchiale
- Bronchiectasis
- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** HSK31858
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06820749
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-10
- **Primary completion:** 2026-04-23
- **Final completion:** 2026-06-22
- **Target enrollment:** 309 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820749, "A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06820749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*